Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions

This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.

Planned

The registry lists NCT07631013 as not yet recruiting, last updated 2026-06-11. Enrolment is 36 planned participants, an estimate. Interventions: TROP2 CAR/IL-15 TGFBR2 KO NK cells. Primary measures include Safety and Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.

Setting

Phase 1 Dose Escalation And Expansion Study Of Intralesional TROP2-CAR/ IL15 TGFBR2 KO Engineered Cord Blood-Derived NK Cells In Patients With Diffused Or Multifocal Oral Premalignant Lesions

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Registry

NCT07631013

Started

2026-12-31 (estimated)

Enrolled

Connected

targets

TROP2

Evidence strength4/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1+4
No structured primary endpoint0
Result: planned0
No independent replication recorded0

Formula disclosed on the evidence page.

Follow this page

Follow by feed

Improve the information

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an edit

Targets

TROP2

Sourced, not expert-reviewedEvery fact here carries a dated source and the automated checks run on every build. Next scheduled re-check 3 February 2027. No named reviewer has signed it off. It is queued for expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT07631013

A source that has moved or gone is reported by the weekly link check. /audit/

Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions

This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.

Planned

Setting

Phase 1 Dose Escalation And Expansion Study Of Intralesional TROP2-CAR/ IL15 TGFBR2 KO Engineered Cord Blood-Derived NK Cells In Patients With Diffused Or Multifocal Oral Premalignant Lesions

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Registry

NCT07631013

Started

2026-12-31 (estimated)

Enrolled

Connected

targets

TROP2

Evidence strength4/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1+4
No structured primary endpoint0
Result: planned0
No independent replication recorded0

Formula disclosed on the evidence page.

Follow this page

Follow by feed

Improve the information

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an edit

Targets

TROP2

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT07631013

A source that has moved or gone is reported by the weekly link check. /audit/

Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions

Overview

Connected

targets

Sources

Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions

Overview

Connected

targets

Sources